Literature DB >> 10116626

The validity of a visual analogue scale in determining social utility weights for health states.

E Nord1.   

Abstract

Asking people to place health states on a visual analogue scale is a commonly used technique for establishing social utility weights for life years. Recently, the technique has been adopted for setting priorities in the Oregon Medicaid Program in the US; as well as by the Euroqol Group in their development of an instrument meant to serve as a tool for linking cross-national valuations of health states. However, it is unclear what people mean when they value health states on a visual analogue scale. In a series of empirical studies, subjects expressed little depth of intention in relation to the valuations beyond the act of ranking states. Comparisons of the valuations, with valuations elicited by means of the equivalence of numbers technique, indicated that intervals between states on the visual analogue scale must be weighted more the closer they are to the bottom of the scale. This is the same as saying that visual analogue scale values should not be used directly as utility weights for life years. A transformation of the values is needed, and a power function may be suitable for this purpose.

Entities:  

Mesh:

Year:  1991        PMID: 10116626     DOI: 10.1002/hpm.4740060308

Source DB:  PubMed          Journal:  Int J Health Plann Manage        ISSN: 0749-6753


  17 in total

1.  Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off.

Authors:  X Badia; S Monserrat; M Roset; M Herdman
Journal:  Qual Life Res       Date:  1999-06       Impact factor: 4.147

Review 2.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

3.  Severity as an independent determinant of the social value of a health service.

Authors:  Jeff R J Richardson; John McKie; Stuart J Peacock; Angelo Iezzi
Journal:  Eur J Health Econ       Date:  2010-05-09

4.  A Norwegian 15D value algorithm: proposing a new procedure to estimate 15D value algorithms.

Authors:  Yvonne Anne Michel; Liv Ariane Augestad; Mathias Barra; Kim Rand
Journal:  Qual Life Res       Date:  2018-11-30       Impact factor: 4.147

5.  An alternative to QALYs: the saved young life equivalent (SAVE)

Authors:  E Nord
Journal:  BMJ       Date:  1992-10-10

6.  Health state valuations from the general public using the visual analogue scale.

Authors:  C Gudex; P Dolan; P Kind; A Williams
Journal:  Qual Life Res       Date:  1996-12       Impact factor: 4.147

7.  A tale of two countries: comparing disability weights for gambling problems in New Zealand and Australia.

Authors:  Vijay Rawat; Matthew Browne; Maria Bellringer; Nancy Greer; Komathi Kolandai-Matchett; Matthew Rockloff; Erika Langham; Christine Hanley; Katie Palmer Du Preez; Max Abbott
Journal:  Qual Life Res       Date:  2018-05-17       Impact factor: 4.147

8.  Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE): Protocol.

Authors:  Kirk I Erickson; George A Grove; Jeffrey M Burns; Charles H Hillman; Arthur F Kramer; Edward McAuley; Eric D Vidoni; James T Becker; Meryl A Butters; Katerina Gray; Haiqing Huang; John M Jakicic; M Ilyas Kamboh; Chaeryon Kang; William E Klunk; Phil Lee; Anna L Marsland; Joseph Mettenburg; Renee J Rogers; Chelsea M Stillman; Bradley P Sutton; Amanda Szabo-Reed; Timothy D Verstynen; Jennifer C Watt; Andrea M Weinstein; Mariegold E Wollam
Journal:  Contemp Clin Trials       Date:  2019-08-26       Impact factor: 2.226

9.  Transforming EQ-5D utilities for use in cost–value analysis of health programs.

Authors:  Erik Nord; Rune Johansen
Journal:  Eur J Health Econ       Date:  2015-04

Review 10.  Methods for assessing relative importance in preference based outcome measures.

Authors:  R M Kaplan; D Feeny; D A Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.